Scientific Innovation: Stakeholder Perceptions and Preferences for Biologics

• In Event: Poster Session: Science, Technology, and Environmental Policy 2 & Comparative Education Reform
  In Poster Session: Poster Session 2: Science, Technology, and Environmental Policy

Abstract

Biologics, a class of therapeutic agents derived from living organisms, have brought revolutionary changes to healthcare. These innovative solutions have displayed unprecedented efficacy in managing a diverse array of diseases and conditions, promising new hope and improved quality of life for many individuals. However, the acceptance of and support for biologic treatments by stakeholders across the healthcare continuum is not static; it is greatly influenced by their beliefs, values, and understanding of boarder societal needs as well as specific attitudes towards the evolving landscape of scientific innovation. The aim of this study is to provide a robust and data-driven comprehension of stakeholder viewpoints, encompassing patients, healthcare professionals, pharmaceutical companies, and manufactures. Each of these stakeholder groups plays an important role in shaping support for biologic therapies, contributing their unique perspectives and needs to the broader healthcare landscape. The study also offers suggestions for developing successful communication strategies to ensure that scientific innovations are effectively translated into healthcare solutions and are aligned with the needs and preferences of all stakeholders, helping to prioritize accessible, efficacious, and patient-centered healthcare.

Authors

• Nataliia Borozdina, University of Arkansas

• Geoboo Song, University of Arkansas, Fayetteville

• Ben Galloway, University of Arkansas